ArticleBMC gastroenterology2025

Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma.

Wenjie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.